The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Influence of Multidrug Resistance and Appropriate Empirical Therapy on the 30-Day Mortality Rate of Pseudomonas aeruginosa Bacteremia
Open accessAbstract
Infections due to multidrug-resistant (MDR) Pseudomonas aeruginosa are increasing. The aim of our study was to evaluate the influences of appropriate empirical antibiotic therapy and multidrug resistance on mortality in patients with bacteremia due to P. aeruginosa (PAB). Episodes of PAB were prospectively registered from 2000 to 2008. MDR was considered when the strain was resistant to ≥3 antipseudomonal antibiotics. Univariate and multivariate analyses were performed. A total of 709 episodes of PAB were studied. MDR PAB ( n = 127 [17.9%]) was more frequently nosocomial and associated with longer hospitalization, bladder catheter use, steroid and antibiotic therapy, receipt of inappropriate empirical antibiotic therapy, and a higher mortality. Factors independently associated with mortality were age (odds ratio [OR], 1.02; 95% confidence interval [CI], 1.002 to 1.033), shock (OR, 6.6; 95% CI, 4 to 10.8), cirrhosis (OR, 3.3; 95% CI, 1.4 to 7.6), intermediate-risk sources (OR, 2.5; 95% CI, 1.4 to 4.3) or high-risk sources (OR, 7.3; 95% CI, 4.1 to 12.9), and inappropriate empirical therapy (OR, 2.1; 95% CI, 1.3 to 3.5). To analyze the interaction between empirical therapy and MDR, a variable combining both was introduced in the multivariate analysis. Inappropriate therapy was significantly associated with higher mortality regardless of the susceptibility pattern, and there was a trend toward higher mortality in patients receiving appropriate therapy for MDR than in those appropriately treated for non-MDR strains (OR, 2.2; 95% CI, 0.9 to 5.4). In 47.9% of MDR PAB episodes, appropriate therapy consisted of monotherapy with amikacin. In conclusion, MDR PAB is associated with a higher mortality than non-MDR PAB. This may be related to a higher rate of inappropriate empirical therapy and probably also to amikacin as frequently the only appropriate empirical therapy given to patients with MDR PAB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 1×
“Similar to previous published experiences (2, 8, 9, 13, 26, 27), the analysis of our patients showed an association between mortality and increasing age, patient’s comorbidity (liver cirrhosis), shock on presentation, the source of infection (respiratory, unknown, and abdominal sources), and the appropriateness of emp…”
ResultWisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Paul, M., Kariv, G., Goldberg, E., Raskin, M., Shaked, H., Hazzan, R., Samra, Z., Paghis, D., Bishara, J., & Leibovici, L. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq373 · Cited by 224 · cited 1×
“Other observations have also supported the importance of appropriate empirical therapy in patients with bacteremia in general (26) or due to particular pathogens, such as methicillin-resistant Staphylococcus aureus (22) or Escherichia coli (21).”
Result
Cited by
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
Jean, S.-S., Harnod, D., & Hsueh, P.-R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.823684 · Cited by 366
Nathwani, D., Raman, G., Sulham, K., Gavaghan, M., & Menon, V. (2014) · Antimicrobial Resistance and Infection Control · doi:10.1186/2047-2994-3-32 · Cited by 344
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D. A., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 334
Hung, Y.-P., Lee, C.-C., & Ko, W.-C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869822 · Cited by 29
Metadata
- Authors
- Morata, L., Cobos-Trigueros, N., Martínez, J. A., Soriano, Á., Almela, M., Marco, F., Sterzik, H., Núñez, R., Hernández, C., & Mensa, J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-09
- Volume
- 56
- Issue
- 9
- Pages
- 4833-4837
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2162282209
- Cited by
- 163
- References
- 3
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.